Opus Genetics
IRD
49 hedge funds and large institutions have $6.78M invested in Opus Genetics in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 9 closing their positions.
1,850% more call options, than puts
Call options by funds: $234K | Put options by funds: $12K
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
2% less funds holding
Funds holding: 50 → 49 (-1)
2.8% less ownership
Funds ownership: 16.4% → 13.6% (-2.8%)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
39% less capital invested
Capital invested by funds: $11.2M → $6.78M (-$4.39M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$282K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$163K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$163K |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$104K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$92.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$710K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$426K |
| 3 |
Squarepoint
New York
|
-$184K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$149K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$141K |
IRD Hedge Fund Activity: Q1 2024 in Review
49 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q1 2024, worth a combined $6.78M — down 39% from $11.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IRD and 8 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 12 added.
The largest buyer was Renaissance Technologies, adding an estimated $282K. The largest seller was Rice Hall James & Associates, cutting an estimated $710K.
- 49 institutional investors held Opus Genetics (IRD) as of Q1 2024, down from 50 in Q4 2023.
- Funds reported $6.78M of Opus Genetics stock for Q1 2024, down 39% quarter-over-quarter.
- 8 funds opened new Opus Genetics positions in Q1 2024 and 9 closed out, a net change of -1 holder.
- The largest Opus Genetics buyer in Q1 2024 was Renaissance Technologies, an estimated $282K added.
- The largest Opus Genetics seller in Q1 2024 was Rice Hall James & Associates, an estimated $710K sold.
Based on aggregated 13F filings for Q1 2024.